Table 1.
Baseline characteristics of the participants
| Characteristic | Total (n=39) |
Control (n=13) |
Low-Dose (n=14) |
High-Dose (n=12) |
P |
|---|---|---|---|---|---|
| Age, years | 56.5 [49.1–63.3] | 56.5 [51.0–60.9] | 59.1 [54.3–66.4] | 54.6 [45.0–62.0] | 0.493 |
| Sex, % | |||||
| Male | 15 (38%) | 4 (31%) | 7 (50%) | 4 (33%) | 0.601 |
| Female | 24 (62%) | 9 (69%) | 7 (50%) | 8 (67%) | |
| Race, % | |||||
| White | 31 (80%) | 8 (62%) | 12 (86%) | 11 (92%) | 0.332 |
| Black | 6 (15%) | 3 (23%) | 2 (14%) | 1 (8%) | |
| Other | 2 (5%) | 2 (15%) | 0 (0%) | 0 (0%) | |
| Caloric Consumption, kcal·d−1 | 1735 [1270–1962] | 1800 [1233–2110] | 1776 [1483–2111] | 1632 [1196–1739] | 0.725 |
| Calories from Carbohydrate, % | 46.8 [39.7–51.3] | 43.5 [36.9–49.4] | 48.7 [46.0–54.8] | 37.7 [45.1–51.3] | 0.261 |
| Moderate or Vigorous Physical Activity, min·d−1 | 15.7±8.7 | 12.2±8.1 | 18.8±9.6 | 15.7±7.3 | 0.174 |
| Body Mass Index, kg·m−2 | 30.3 [25.3–35.3] | 29.0 [25.0–33.5] | 30.4 [27.1–32.1] | 33.6 [25.6–37.7] | 0.408 |
| Waist Circumference, cm | 102 [91–110] | 94 [90–107] | 99 [91–107] | 109 [110–114] | 0.154 |
| Visceral Adipose Tissue, cm2 | 130.8 [82.2–168.8] | 116.7 [61.4–150.3] | 133.0 [82.2–162.1] | 138.8 [117.4–206.6] | 0.227 |
| Cancer Stage, % | |||||
| I | 5 (13%) | 1 (8%) | 2 (14%) | 2 (17%) | 0.999 |
| II | 14 (36%) | 5 (38%) | 5 (36%) | 4 (33%) | |
| III | 20 (51%) | 7 (54%) | 7 (50%) | 6 (50%) | |
| Chemotherapy, % | 28 (72%) | 10 (77%) | 10 (71%) | 8 (67%) | 0.906 |
| Time Since Treatment, Months | 10 [5–16] | 12 [8–16] | 7.5 [4–13] | 10 [6–17] | 0.417 |
| Comorbid Conditions, % | |||||
| Hypertension | 13 (33%) | 4 (31%) | 6 (43%) | 3 (25%) | 0.695 |
| Hyperlipidemia | 6 (15%) | 1 (8%) | 2 (14%) | 3 (25%) | 0.480 |
| Type 2 Diabetes | 5 (13%) | 1 (8%) | 1 (7%) | 3 (25%) | 0.409 |
| Cardiovascular Disease | 4 (10%) | 2 (15%) | 1 (7%) | 1 (8%) | 0.827 |
P values are from the overall test of group differences. Data are median [interquartile range], or counts with percentages.